Jiri Pavlu is a Consultant Haematologist at Hammersmith Hospital and Honorary Clinical Senior Lecturer at Imperial College London. He graduated from the First Faculty of Medicine of Charles University in Prague in 1998. In completing this he was part of the research group of Professor Gordon-Smith at St.Georges Hospital Medical School in London and obtained his research degree in molecular haematology. He completed his specialist haematology training in London on the Royal Free and Hammersmith rotation.
He has developed a specialist interest in haematopoietic stem cell transplantation, particularly for leukaemia. He is the clinical lead for acute leukaemia and myelodysplastic syndromes and a stem cell transplant clinical and collection facility director. Together with Gill Brisley, clinical nurse specialist, and the transplant coordinators he runs relevant specialist haematology clinics at Hammersmith Hospital. He is a principal investigator and subinvestigator of various clinical trials, an active member of the European Group for Blood and Marrow Transplantation (EBMT) Acute leukaemia working party and also an accredited inspector for the Joint Accreditation Committee – International Society for Cellular Therapy (Europe) & EBMT.
Secretary: +44 (0) 2083838117, +44 (0) 2083835030
Fax: +44 (0) 2033133965
et al., 2021, How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia., Clin Hematol Int, Vol:3, Pages:130-141
et al., 2021, Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy, British Journal of Haematology, Vol:196, ISSN:0007-1048, Pages:368-373
et al., 2021, Fecal microbiota transplant mitigates adverse outcomes in patients colonized with multidrug-resistant organisms undergoing allogeneic hematopoietic cell transplantation, Frontiers in Cellular and Infection Microbiology, Vol:11, ISSN:2235-2988, Pages:1-8
et al., 2021, High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma, Bone Marrow Transplantation, Vol:56, ISSN:0268-3369, Pages:2690-2696
et al., 2021, Comparison of Haploidentical Peripheral Blood Cell Transplantation Using Post-Transplant Cyclophosphamide With Double Cord Blood Transplantation in Adults With Acute Leukemia, SPRINGERNATURE, Pages:24-25, ISSN:0268-3369